GlobalData on MSN12d
Genprex links with University of Michigan on lung cancer treatment
Genprex intellectual property and licensing senior vice-president Thomas Gallagher stated: “We continue to bolster our ...
Lung cancer coverage in SC needs expansion, genetic testing coverage, lung group says
She didn't smoke but got advanced lung cancer. Genetic testing opened the door to targeted therapies. South Carolina doesn't ...
Genprex signs exclusive license agreement with University of Michigan
Genprex (GNPX) announced it has entered into an exclusive license agreement with the University of Michigan, granting Genprex a worldwide, ...
pharmaphorum8d
NICE backs first targeted therapy for ALK+ lung cancer
Roche's Alecensa has been recommended for routine NHS use as an adjuvant treatment for ALK-positive non-small cell lung cancer (NSCLC), the first targeted therapy for this indication. Alecensa ...
Nasdaq13d
Genprex Signs Exclusive License to Additional Gene Therapy Technologies with the University of Michigan for the Treatment of Lung Cancer
License includes Genprex's Reqorsa® Gene Therapy in Combination with ALK-Inhibitors for the Potential Treatment of ALK-Positive Lung ... pathways that cause replication and proliferation of ...
National Institute for Health and Care Excellence21d
Alectinib for adjuvant treatment of ALK-positive non-small-cell lung cancer
Alectinib is recommended, within its marketing authorisation, as an option for the adjuvant treatment of stage 1B (tumours 4 cm or larger) to 3A ALK-positive non-small-cell lung cancer (NSCLC) after ...
Stockhouse14d
Genprex Signs Exclusive License to Additional Gene Therapy Technologies with the University of Michigan for the Treatment of Lung Cancer
REQORSA has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication ... as a therapeutic treatment in combination with ALK-inhibitors for ALK-positive ...